A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse.

Trial Profile

A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Exelixis
  • Most Recent Events

    • 27 Jun 2017 Converging evidence from 5 seperate phase II trials (NCT00035656, NCT00345163, NCT00704288, NCT00369590 and NTR1929) results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Feb 2013 Planned end date changed from 1 Dec 2011 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top